Loading...
XNASVCEL
Market cap2.94bUSD
Jan 10, Last price  
59.50USD
1D
-0.05%
1Q
42.72%
Jan 2017
1,883.33%
Name

Vericel Corp

Chart & Performance

D1W1MN
XNAS:VCEL chart
P/E
—
P/S
14.87
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.41%
Rev. gr., 5y
16.80%
Revenues
198m
+20.17%
1,302,000909,000863,000685,000522,000182,00089,00018,00021,00019,00028,796,00051,168,00054,383,00063,924,00090,857,000117,850,000124,179,000156,184,000164,365,000197,516,000
Net income
-3m
L-80.96%
-10,488,000-11,811,000-16,475,000-17,594,000-20,133,000-15,946,000-17,729,000-19,668,000-29,474,000-15,622,000-19,920,000-16,340,000-19,566,000-17,286,000-8,137,000-7,909,0002,864,000-7,471,000-16,709,000-3,182,000
CFO
35m
+99.64%
-9,525,000-11,065,000-13,518,000-14,826,000-19,527,000-13,805,000-15,085,000-24,492,000-29,545,000-19,943,000-25,410,000-13,346,000-19,892,000-13,183,000-412,000-7,183,00017,572,00029,040,00017,687,00035,311,000
Earnings
Feb 26, 2025

Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
URL
https://vcel.com/
IPO date
Feb 04, 1997
Employees
305
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
197,516
20.17%
164,365
5.24%
Cost of revenue
82,982
74,520
Unusual Expense (Income)
NOPBT
114,534
89,845
NOPBT Margin
57.99%
54.66%
Operating Taxes
814
721
Tax Rate
0.71%
0.80%
NOPAT
113,720
89,124
Net income
(3,182)
-80.96%
(16,709)
123.65%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,000
3,652
BB yield
-0.35%
-0.29%
Debt
Debt current
12,374
4,302
Long-term debt
169,899
90,838
Deferred revenue
Other long-term liabilities
100
Net debt
47,433
(44,360)
Cash flow
Cash from operating activities
35,311
17,687
CAPEX
(7,596)
Cash from investing activities
(3,130)
(36,206)
Cash from financing activities
3,618
1,045
FCF
27,463
88,575
Balance
Cash
109,557
119,538
Long term investments
25,283
19,962
Excess cash
124,964
131,282
Stockholders' equity
225,952
192,272
Invested Capital
195,318
108,560
ROIC
74.85%
85.74%
ROCE
35.76%
37.46%
EV
Common stock shares outstanding
47,590
47,130
Price
35.61
35.19%
26.34
-32.98%
Market cap
1,694,680
36.51%
1,241,404
-32.03%
EV
1,742,113
1,197,044
EBITDA
119,166
93,826
EV/EBITDA
14.62
12.76
Interest
600
366
Interest/NOPBT
0.52%
0.41%